Day: March 6, 2023

Reata Pharmaceuticals, Inc. has received approval from the U.S. Food and Drug Administration (FDA) for SKYCLARYS™ (omaveloxolone) to treat Friedreich’s ataxia (FA) in adults and adolescents aged … Read more